Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study
| Autor: | Bernardo Marquez, Kristine Ashcraft, Susan Rojahn, Elif Tokar Erdemir, Taryn O. Hall, Gwyn Omar Magoncia, Justine Reyes, Yinglong Guo, Chantelle Schenning, Kae Vines Tanudtanud, Chad Moretz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
medication management hierarchical conditions category (HCC) precision medicine Medicine (miscellaneous) Pharmacy risk adjustment factor (RAF) Medicare Advantage Article healthcare costs length of stay Diabetes mellitus Internal medicine medicine Disease burden pharmacogenomics COPD business.industry COVID-19 Retrospective cohort study medicine.disease healthcare administration Pharmacogenomics Medicine business Pharmacogenetics hospitalization |
| Zdroj: | Journal of Personalized Medicine Journal of Personalized Medicine, Vol 11, Iss 1192, p 1192 (2021) Volume 11 Issue 11 |
| ISSN: | 2075-4426 |
| Popis: | Unmanaged pharmacogenomic and drug interaction risk can lengthen hospitalization and may have influenced the severe health outcomes seen in some COVID-19 patients. To determine if unmanaged pharmacogenomic and drug interaction risks were associated with longer lengths of stay (LOS) among patients hospitalized with COVID-19, we retrospectively reviewed medical and pharmacy claims from 6025 Medicare Advantage members hospitalized with COVID-19. Patients with a moderate or high pharmacogenetic interaction probability (PIP), which indicates the likelihood that testing would identify one or more clinically actionable gene–drug or gene–drug–drug interactions, were hospitalized for 9% (CI: 4–15% p < 0.001) and 16% longer (CI: 8–24% 0.001), respectively, compared to those with low PIP. Risk adjustment factor (RAF) score, a commonly used measure of disease burden, was not associated with LOS. High PIP was significantly associated with 12–22% longer LOS compared to low PIP in patients with hypertension, hyperlipidemia, diabetes, or chronic obstructive pulmonary disease (COPD). A greater drug–drug interaction risk was associated with 10% longer LOS among patients with two or three chronic conditions. Thus, unmanaged pharmacogenomic risk was associated with longer LOS in these patients and managing this risk has the potential to reduce LOS in severely ill patients, especially those with chronic conditions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|